Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.sparc.life | |
Market Cap | 6,247.04 Cr. | |
Enterprise Value(EV) | 6,466.88 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -7.32 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-09 |
Industry PE | 32.78 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | -8.28 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | -23.24 | Calculated using Price: 192.50 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 32.45 Cr. | 324,521,588 Shares |
FaceValue | 1 | |
Company Profile | ||
The company is engaged in the pharmaceutical research and development. The company's core focus is innovation and new product development for global markets. SPARC undertakes projects in research and technology for new chemical entities (NCE's) or new molecules, and novel drug delivery systems (NDDS). |
1 Day |
|
-0.62% |
1 Week |
|
-4.58% |
1 Month |
|
-7.26% |
3 Month |
|
-23.02% |
6 Month |
|
-15.86% |
1 Year |
|
-38.34% |
2 Year |
|
+8.31% |
5 Year |
|
-58.43% |
10 Year |
|
+79.86% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 24.62 | -33.17 | -109.16 | -127.40 | -156.84 | -74.72 | -225.08 | |||
Return on Capital Employed (%) | 24.02 | -31.74 | -71.37 | -94.66 | -113.05 | -59.95 | -178.95 | -254.10 | -225.57 | |
Return on Assets (%) | 15.29 | -23.65 | -44.68 | -53.72 | -66.85 | -40.89 | -93.11 | -60.18 | -79.80 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 139 | 100 | 32 | 158 | 185 | 296 | -19 | -168 | 31 | -119 | |
Non Curr. Liab. | 9 | 10 | 10 | 10 | 12 | 7 | 56 | 165 | 77 | 82 | |
Curr. Liab. | 39 | 37 | 125 | 108 | 116 | 95 | 235 | 233 | 171 | 329 | |
Minority Int. | |||||||||||
Equity & Liab. | 188 | 147 | 167 | 277 | 313 | 398 | 273 | 230 | 280 | 292 | |
Non Curr. Assets | 77 | 83 | 99 | 118 | 138 | 141 | 205 | 167 | 209 | 219 | |
Curr. Assets | 110 | 63 | 67 | 158 | 175 | 257 | 67 | 63 | 71 | 73 | |
Misc. Exp. not W/O | 1 | 0 | 1 | ||||||||
Total Assets | 188 | 147 | 167 | 277 | 313 | 398 | 273 | 230 | 280 | 292 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 167 | 156 | 161 | 181 | 78 | 183 | 77 | 253 | 137 | 147 | |
Other Income | 10 | 3 | 3 | 14 | 5 | 14 | 10 | 5 | 7 | 1 | |
Total Income | 177 | 159 | 164 | 195 | 83 | 196 | 87 | 258 | 144 | 148 | |
Total Expenditure | -134 | -191 | -224 | -304 | -321 | -334 | -387 | -388 | -324 | -366 | |
PBIDT | 43 | -32 | -60 | -109 | -238 | -138 | -300 | -130 | -180 | -218 | |
Interest | -6 | 0 | -2 | -2 | 0 | 0 | -3 | -11 | -13 | -9 | |
Depreciation | -4 | -7 | -8 | -8 | -8 | -8 | -9 | -11 | -10 | -11 | |
Taxation | -4 | ||||||||||
Exceptional Items | 49 | ||||||||||
PAT | 30 | -40 | -70 | -119 | -197 | -145 | -312 | -151 | -203 | -238 | |
Adjusted EPS | 1 | -2 | -3 | -5 | -8 | -6 | -12 | -6 | -7 | -9 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | -95 | 37 | -41 | -44 | -128 | -183 | -172 | -211 | -152 | -208 | |
Cash Fr. Inv. | -99 | 44 | 53 | -13 | -7 | -105 | -102 | 155 | 2 | -29 | |
Cash Fr. Finan. | 194 | -81 | -1 | 51 | 194 | 224 | 274 | 55 | 159 | 229 | |
Net Change | 0 | 0 | 11 | -7 | 60 | -63 | 0 | 9 | -8 | ||
Cash & Cash Eqvt | 0 | 0 | 11 | 4 | 64 | 0 | 0 | 0 | 9 | 1 |
Fri, 27 Jan 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of loss of share certificate by the holder |
Wed, 25 Jan 2023
"Launch Of SEZABY (Phenobarbital Sodium Powder For Injection) In The U.S. For The Treatment Of Neonatal Seizures". We would like to inform that the Company has received an intimation from the partner about the launch of SEZABY (phenobarbital sodium powder for injection) in the U.S. for the treatment of neonatal seizures. The Company is eligible to receive US$ 5 million as milestone payment upon commercialization of SEZABY the first and only product approved in U.S. for the treatment of neonatal seizures in term and preterm infants.Pursuant to the agreement between the parties SPARC shall also be eligible for future milestones and royalties on net sales. |
Fri, 20 Jan 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of loss of share certificate by the holder |
Mon, 30 Jan 2023 |
|
|
|
|
|